[1] RAY K. NAFLD-the next global epidemic . Nat Rev Gastroenterol Hepatol, 2013, 10:621.
[2] Macut D, Bozic-antic I, Bjekic-macut J, et al. MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease . Eur J Endocrinol, 2017, 177:R145-R58.
[3] Brzozowska MM, Ostapowicz G, Weltman MD. An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome . J Gastroenterol Hepatol, 2009, 24:243-247.
[4] Vassilatou E, Vassiliadi DA, Salambasis K, et al. Increased prevalence of polycystic ovary syndrome in premenopausal women with nonalcoholic fatty liver disease . Eur J Endocrinol, 2015, 173:739-747.
[5] Kumarendran B, O'reilly m W, Manolopoulos KN, et al. Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database . PLoS Med, 2018, 15:e1002542.
[6] Cai J, Wu CH, Zhang Y, et al. High-free androgen index is associated with increased risk of non-alcoholic fatty liver disease in women with polycystic ovary syndrome, independent of obesity and insulin resistance . Int J Obes (Lond), 2017, 41:1341-1347.
[7] Ramezani-Binabaj M, Motalebi M, Karimi-Sari H, et al. Are women with polycystic ovarian syndrome at a high risk of non-alcoholic Fatty liver disease; a meta-analysis. Hepat Mon, 2014, 14:e23235.
[8] Zain SM, Mohamed Z, Mohamed R. A common variant in the glucokinase regulatory gene rs780094 and risk of nonalcoholic fatty liver disease: A meta-analysis . J Gastroen Hepatol, 2015, 30:21-27.
[9] Allemand MC, Irving BA, Asmann YW, et al. Effect of testosterone on insulin stimulated IRS1 Ser phosphorylation in primary rat myotubes-A potential model for PCOS-related insulin resistance. Plos One, 2009, 4:e4274.
[10] Zhang Y, Meng F, Sun X, et al. Hyperandrogenism and insulin resistance contribute to hepatic steatosis and inflammation in female rat liver. Oncotarget, 2018, 9:18180-18197.
[11] Dai R, Yan D, Li J, et al. Activation of PKR/eIF2alpha signaling cascade is associated with dihydrotestosterone-induced cell cycle arrest and apoptosis in human liver cells. J Cell Biochem, 2012, 113:1800-1808.
[12] Dawson AJ, Sathyapalan T, Smithson JAJ, et al. A comparison of cardiovascular risk indices in patients with polycystic ovary syndrome with and without coexisting nonalcoholic fatty liver disease. Clin Endocrinol, 2014, 80:843-849.
[13] Cerda C, Perez-ayuso RM, Riquelme A, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol, 2007, 47:412-417.
[14] Hagstrom H, Hoijer J, Ludvigsson JF, et al. Adverse outcomes of pregnancy in women with non-alcoholic fatty liver disease. Liver Int, 2016, 36:268-274.
[15] Gangale MF, Miele L, Lanzone A, et al. Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome . Clin Endocrinol, 2011, 75:520-527.
[16] Frossing S, Nylander M, Chabanova E, et al. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial . Diabetes Obes Metab, 2018, 20:215-218.
[17] Sathyapalan T, Atkin S L. Evidence for statin therapy in polycystic ovary syndrome. Ther Adv Endocrinol Metab, 2010, 1:15-22.
[18] Ebrahimi FA, Samimi M, Foroozanfard F, et al. The effects of omega-3 fatty acids and vitamin E co-supplementation on indices of insulin resistance and hormonal parameters in patients with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Exp Clin Endocrinol Diabetes, 2017, 125:353-359.
[19] Genazzani AD, Shefer K, Della Casa D, et al. Modulatory effects of alpha-lipoic acid (ALA) administration on insulin sensitivity in obese PCOS patients. J Endocrinol Invest, 2018, 41:583-590.
[20] Gomez-meade CA, Lopez-mitnik G, Messiah SE, et al. Cardiometabolic health among gastric bypass surgery patients with polycystic ovarian syndrome. World J Diabetes, 2013, 4:64-69. |
